Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

Gout is severely debilitating disease that affects 1-4 percent of adults. It is a form of arthritis that is characterized by red, hot, inflamed joints. It is the most common form of inflammatory arthritis in adults and can cause chronic disability and joint destruction. Approximately 90% of patients with gout have another co-existing disease, making them ineligible for many of existing gout treatments.

The first study found that ACZ885 reduced pain by an additional 29% on a visual analog scale when compared to TA, and nearly double the number of patients who received TA doses experienced a second gout attack within three months.

The second study expressed similar results, with ACZ885 reducing pain by an additional 31%, with nearly thee times as many patients in the TA group experiencing a second attack within three months.

Novartis had applied for approval of Ilaris in gouty arthritis patients with limited treatment options in the EU last year and in the United States, Canada and Switzerland in the first quarter of this year. The drug is already approved in several countries to treat a rare, inflammatory disorder known as Cryopyrin-Associated Periodic Syndromes (CAPS). The drug maker is also studying Ilaris in other diseases in which IL-1 beta plays a role in causing inflammation, such as cardiovascular disease and diabetes.

This drug, say the developers targets interleukin-1 beta that is the root cause of pain in gouty arthritis. The results of the study will be presented at this year's European League Against Rheumatism (EULAR) Congress in London.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2019, June 20). Gout drug success for Novartis. News-Medical. Retrieved on February 20, 2024 from https://www.news-medical.net/news/20110526/Gout-drug-success-for-Novartis.aspx.

  • MLA

    Mandal, Ananya. "Gout drug success for Novartis". News-Medical. 20 February 2024. <https://www.news-medical.net/news/20110526/Gout-drug-success-for-Novartis.aspx>.

  • Chicago

    Mandal, Ananya. "Gout drug success for Novartis". News-Medical. https://www.news-medical.net/news/20110526/Gout-drug-success-for-Novartis.aspx. (accessed February 20, 2024).

  • Harvard

    Mandal, Ananya. 2019. Gout drug success for Novartis. News-Medical, viewed 20 February 2024, https://www.news-medical.net/news/20110526/Gout-drug-success-for-Novartis.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Stair climbing study unveils surprising link to back pain in females but not males